Circulating tumor cells as liquid biopsy for castration resistant prostate cancer patients treated with cabazitaxel

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel

Background Treatment selection for men with metastatic castration-resistant prostate cancer (mCRPC) has become increasingly challenging with the introduction of novel therapies at earlier disease stages. The purpose of this study was to identify prognostic factors for overall survival (OS) and PSA response in patients with mCRPC treated with cabazitaxel. Results 224 mCRPC patients were includ...

Circulating tumor cells: liquid biopsy of cancer.

BACKGROUND The detection and molecular characterization of circulating tumor cells (CTCs) are one of the most active areas of translational cancer research, with >400 clinical studies having included CTCs as a biomarker. The aims of research on CTCs include (a) estimation of the risk for metastatic relapse or metastatic progression (prognostic information), (b) stratification and real-time moni...

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel

Dear Editor, About 20-40% of patients who undergo primary therapy for early-stage prostate cancer, experience biochemical relapse of which 30-70% develop metastatic disease within 10 years1 and the majority will become resistant to castration (CRPC). Since 2004, docetaxel has been the first-line cytotoxic treatment in treating metastatic CRPC. However, many mCRPC patients eventually become resi...

Using circulating tumor cells as a prognostic indicator in metastatic castration-resistant prostate cancer.

A more reliable tumor marker is needed as a prognostic indicator in metastatic castration-resistant prostate cancer. Circulating tumor cells (CTCs) are cells that have broken away from a tumor and flow in the bloodstream. Evidence has indicated that the presence of CTCs in the peripheral blood of men with solid malignancies correlates with clinical outcomes. When the CTC number is reduced to fe...